Start with a defined cause
Focus on inherited CSVD where variants in COL4A1 or NOTCH3 give a precise biological starting point.
Roadmap
How inherited CSVD research moves toward targeted treatment.
A focused route from genetic cause to credible therapeutic evidence for COL4A1-related disease and CADASIL.
Therapeutic direction
Keep the science close to the disease, the evidence, and the people affected.
CSVD Therapeutics is building a practical translational path for inherited cerebral small vessel disease. The work begins with defined genetic causes, uses disease-relevant models to test candidate interventions, and prioritizes the evidence needed before any treatment concept can be responsibly moved toward patients.
Test disease-relevant systems
Use cellular and vascular readouts to ask whether candidate therapies change measurable disease biology.
Develop credible interventions
Evaluate approaches such as plasmid systems, viral vectors, ASOs, CRISPR strategies, and drug repurposing where appropriate.
Build readiness for patients
Connect biomarkers, safety, delivery, natural history, and patient priorities into the evidence package needed for future trials.
